Real-world data (RWD) is defined as data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings.

The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%.

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).

The rising focus on end-to-end RWE services and growth opportunities in emerging markets are expected to provide further growth opportunities for players operating in the real world evidence market.

However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection some of the factors limiting the growth of this market during the forecast period.

Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 Real World Evidence Market, By Component IntroductionData SetsClinical Setting DataClaims DataPharmacy DataPatient Powered DataServicesReal World Evidence Market, By Therapeutic Area OncologyCardiovascular DiseaseNeurologyImmunologyOthers Therapeutic AreasReal World Evidence Market, By End User Pharmaceutical and Medical Device CompaniesHealthcare PayersHealthcare ProvidersOther End UsersReal world evidence Market, By Region North AmericaUSCanadaEuropeGermanyUKFranceItalySpainRest Of EuropeAsia Pacific (APAC)ChinaJapanRest of APACRest of the WorldKey Players The prominent players in the global real world evidence solutions market are IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

Palantir Technologies (NYSE:PLTR) today issued additional details about the Palantir Foundry capabilities it will be highlighting in its Life Sciences demo at “Double Click” on Wednesday, April 14, 2021, at 11:00am ET.Palantir’s customers in Life Sciences span pharmaceuticals, research institutions, healthcare systems, and others.

These customers rely on Foundry’s secure and collaborative architecture to discover and develop drugs, manage commercial launches, conduct clinical research, and distribute vaccines.

For example:More than 1,000 researchers at the NIH’s National COVID Cohort Collaborative (N3C) use Foundry to securely maintain one of the largest patient-level data assets of COVID-19 Electronic Health Record (EHR) data in the world and collaborate on more than 150 research projects (as illustrated in this video demonstration by N3C).Thousands of General Practitioners at NHS England order, allocate, track, and deliver every one of the 29+ million vaccines administered in the country to date (as outlined in the UK Government’s website for data and insights on COVID-19).At the first installment of Palantir’s Double Click series, engineers will demo the latest Foundry capabilities, as well as several new Archetypes available on top of Foundry that make this work possible in a matter of clicks, including:Reproducible research in any environment.

Foundry’s interoperable, modular, and open architecture enables users of varying technical ability to integrate any data, use any tool, manage any model, and write code in any language — while maintaining end-to-end reproducibility, transparency, and security of their analyses.

Foundry’s Purpose-Based Access Controls Archetype enables automated or managed assignment of permissions based on the proposed use of a particular data source or dataset.

Foundry’s Model Management Archetype supports the governance and deployment of predictive models, including those developed outside Foundry.